Bridging and Disease Status Before CD19 CAR T

An EBMT and GoCART analysis of 1,134 adults receiving commercial CD19 CAR T for relapsed or refractory large B-cell lymphoma found that 79.5% received bridging therapy. The clinically actionable signal is the association between…




